Economic Burden Analysis of Parkinson’s Disease Patients in China

Abstract

Background and Objective Parkinson's Disease (PD) is a progressive neurodegenerative disorder, which is prevalent in people over 65 years old. PD reduces patients' quality of life and exerts a heavy economic burden on patients and their families. The purpose of this research is to identify the costs of PD and to evaluate the economic distribution of medical care for PD patients in China. Methods A professional survey was administered to 116 patients with PD. Records of medical cost were reviewed. Direct and indirect costs were analyzed. The main cost-driving factors of PD were identified using multivariate regression analysis. Results The average annual cost per PD patient in China is $3,225.94, with direct and indirect costs accounting for $2,503.46 and $722.48, respectively. Direct costs consist of $556.27 for surgery, $44.67 for appointment fees, $605.67 for prescription medication, $460.29 for hospitalization, $71.03 for auxiliary examination, $35.64 for transportation, $10.39 for special equipment, and $719.50 for formal care. The total cost is closely related to surgical treatment, dopamine agonist, and levodopa costs. Conclusion The cost of PD patients in China is considerable and exceeds average economic capacity, especially antiparkinson medication and caring costs. This study may provide a reference for PD healthcare optimization in the future.

<p>Therapeutic strategies in the early stages of Parkinson&rsquo;s disease: a cross-sectional evaluation of 15&nbsp;years&rsquo; experience with a large cohort of Romanian patients</p>

“…However, in a recent study published in 2017, the rate of application of DAs was 67.26%, despite the fact that DAs are being described as a decisive cost-increasing factor. Data from this article also show that the proportion of MAO-Bi is 16.38%, which is lower than the proportion found in Germany, with a MAO-Bi application rate of 26.9% 28. According to a 2013 study of PD in the Scandinavian countries, DAs are more common in Norway (37% of examined patients) than in Sweden (16%).…”

Cost of Cerebellar Ataxia in Hong Kong: A Retrospective Cost-of-Illness Analysis

“…Besides, we also used SARA scores to subcategorise our patients based on their independence in ADL, which arguably exhibits better accuracy. A study published in China which has a comparable healthcare system to that of Hong Kong reported the annual cost of Parkinson's disease as HKD 24,995 (currency converted to base-year 2019) ( 23 ). The estimated lower cost for patients with Parkinson's disease could be due to the lower contribution of productivity loss as Parkinson disease is common among older adults who may have retired during disease onset and secondly, we estimated cost based on unsubsidized charges while they estimated the actual amount paid by the patient with Parkinson's disease in China.…”

Parkinson’s disease in China: a forty-year growing track of bedside work

“…In the year of 2004–2005, the overall mean annual cost of PD in Shanghai was 925 USD, and the direct medical care cost was 519 USD (56.1%) [45]. In the year of 2015, the overall mean annual cost of PD increased to 3,225.94 USD, and the direct medical care cost was 1,737.93 USD (53.9%) in Tianjin [46]. However, The percentage of overall mean annual cost of PD in GDP per capita was only increased slightly (2004: 16.21%; 2015: 17.46%).…”